Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Investigating red blood cells of sickle cell patients who started therapy.

- candidate number28105
- NTR NumberNTR6779
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR26-okt-2017
- Secondary IDsNL62011.041.17 / 17/397 ccmo (toetsing online) / METC
- Public TitleInvestigating red blood cells of sickle cell patients who started therapy.
- Scientific TitleInvestigating red blood cell deformability of sickle cell patients before and after the start of therapy.
- ACRONYMSickleCellScreen
- hypothesisRed blood cell deformability improves after start of therapy with Hydroxyurea.
- Healt Condition(s) or Problem(s) studiedSickle Cell anemia, HbSC, HbSS
- Inclusion criteria1.h No blood transfusion within the past 2 months
2. Diagnosed with sickle cell anemia (HbSS, HbSC or HbS/beta-thal)
3. Starting with Hydroxyurea therapy
4. Parents/legal guardians (and child, depending on age) or adult patients must give informed consent
- Exclusion criteria1. Blood transfusion within past 2 months
2. Body weight below 10 kg
3. Age <1 year
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- group[default]
- Type[default]
- Studytypeobservational
- planned startdate 1-nov-2017
- planned closingdate1-okt-2018
- Target number of participants20
- InterventionsNot applicable
- Primary outcomeRed blood cell deformability
- Secondary outcomeChanges in red blood cell deformability over time and correlations with other laboratory parameters and clinical symptoms and signs.
- Timepointsbaseline, after 1, 3 and 6 months.
- Trial web site
- statusplanned
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
RR Mechatronics
- Publications
- Brief summarySickle cell disease (SCD) is a hemoglobinopathy in which a single nucleotide mutation in the beta-globin chain causes the formation of the abnormal hemoglobin S (HbS). When HbS becomes deoxygenated it polymerises, resulting in sickling of red blood cells (RBCs). These sickled RBCs have strongly reduced deformability, leading to vaso-occlusive crises, multi organ failure and chronic hemolytic anemia.
Hydroxyurea is the only approved drug for the treatment of sickle cell disease. It increases the production of fetal hemoglobin (HbF), thereby lowering HbS levels and, consequently, decreases sickling events. There is however no accurate measurement of a dose-and-effect relation, other than the next life-threatening crisis. There also is no all-inclusive surrogate end-point to estimate disease severity.
Altered red blood cell (RBC) deformability is a feature of many RBC disorders, including SCD. It can be measured using the Lorrca (Laser-assisted Optical Rotational Red Cell Analyzer) under varying circumstances. For instance, the hypoxia-hyperoxia ektacytometry module of the Lorrca enables the measurement of RBC deformability in response to changes in oxygen tension. This is particularly relevant in the field of SCD. Variables known to be of influence for sickling (e.g. HbF levels, presence of transfusion blood) can be studied by using one single fully automated, operator independent test. We hypothesize that this single test can determine an individuals status and/or susceptibility to sickling, and measure the effect of hydroxyurea therapy.
- Main changes (audit trail)
- RECORD26-okt-2017 - 25-nov-2017

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar